- An FDA advisory panel on Wednesday voted in favor of Gilead Sciences Inc’s combination drug to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex with men.
When asked to assess the efficacy of Descovy for pre-exposure prophylaxis of HIV in men and transgender women who have sex with men, a patient population that forms the largest component of the PrEP market, the panel voted 16-2 in favor. Descovy’s entry into the still underpenetrated PrEP market is vital to Gilead’s attempts to retain its Truvada patient base after the drug goes off-patent, he said.The panel’s backing also comes as a possible launch of Descovy for PrEP faces opposition from patient advocacy groups.
Ochocuatro on the list?
The lack of social awareness of this image and headline is quite surprising for a news organization.
That’s laughable! I could cure it in all people but there’s no way on GOD’S Green Earth! I’ve already passed it on but there is no way!!!
Poor choice in headline. Women are not a tiny fraction of the world. Maybe 'but only for men' would be a better choice?
Blessed be the fruit
Poor choice in business name